Pergolide is a potent agonist at dopamine receptors D1 and D2 and is 10 – 1000 times more potent than bromocriptine. It is thought that pituitary pars intermedia dysfunction (PPID) in horses is a dopaminergic degenerative disease and pergolide (or dopamine) can reduce expression of proopiomelanocortin (POMC) peptides from the pars intermedia. These peptides are implicated in causing the signs associated with PPID.
The primary use for pergolide in veterinary medicine is in treatment of horses for pituitary pars intermedia dysfunction (PPID), commonly called equine Cushing’s disease.
劑量數字暫停提供：VetPro 的劑量改依 DRUGAPI 藥物資料庫對外的內容，DRUGAPI 目前不提供可直接計算的劑量。下方列出 DRUGAPI 的審查結論與劑量審查引用的來源；計算機可手動輸入劑量換算。
確認精確產品、法域與有效成分含量基準 確認馬匹資格、PPID 診斷、繁殖與食用動物限制 由獸醫依精確產品標示評估反應、不耐受與監測
DRUGAPI 劑量審查引用的獸醫官方標示（各標示只適用於其產品、物種與法域，不可互換）
依出現頻率分組；嚴重副作用獨立列出，臨床上需立即辨識。